CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Valencia, Spain and 125 other locations
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Valencia, Spain and 164 other locations
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Valencia, Spain and 33 other locations
when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...
Phase 3
Valencia, Valenciana, Spain and 108 other locations
This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. ...
Phase 3
Valencia, Spain and 110 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
València, Spain and 73 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Valencia, Spain and 33 other locations
Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML...
Phase 1
Valencia, Spain and 6 other locations
when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progr...
Phase 2
Valencia, Spain and 42 other locations
inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...
Phase 1, Phase 2
València, Spain and 34 other locations
Clinical trials
Research sites
Resources
Legal